A lack or delayed response to Cablivi (caplacizumab-yhdp), when used alongside standard therapy to treat acute episodes of immune-mediated…
Articles by Steve Bryson PhD
U.S. researchers have created a prediction tool — one that uses laboratory tests collected at the time of diagnosis —…
Researchers are developing a potential treatment for immune-mediated thrombotic thrombocytopenic purpura (iTTP) that promotes immune tolerance rather than immunosuppression,…
A real-world study has found that during hospitalizations among people with von Willebrand disease (VWD), VWF replacement therapy with…
Treatment with Cablivi (caplacizumab-yhdp) as an add-on to standard therapy significantly reduced the number of daily plasma exchange (PEX) treatments…
Scientists have developed a gene-editing therapy to selectively disable the genetic mutations responsible for Von Willebrand disease (VWD) type…
Adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are in remission experience worse health-related quality of life (HRQoL), anxiety,…
Bleeding Disorders News brought you daily coverage of the latest clinical research and scientific breakthroughs related to bleeding disorders…
The cases of adult siblings in Israel, both diagnosed with infantile-onset acquired thrombotic thrombocytopenic purpura (TTP) as children, led…
Doctors found that immune thrombocytopenia (ITP) complicated the surgical removal of a slow-growing, benign tumor along the spine of a…